Cargando...

Long-Term Safety and Efficacy of Enzyme Replacement Therapyfor Fabry Disease

Elsewhere, we reported the safety and efficacy results of a multicenter phase 3 trial of recombinant human α-galactosidase A (rh-αGalA) replacement in patients with Fabry disease. All 58 patients who were enrolled in the 20-wk phase 3 double-blind, randomized, and placebo-controlled study received s...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Wilcox, William R., Banikazemi, Maryam, Guffon, Nathalie, Waldek, Stephen, Lee, Philip, Linthorst, Gabor E., Desnick, Robert J., Germain, Dominique P.
Formato: Artigo
Idioma:Inglês
Publicado: The American Society of Human Genetics 2004
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1182009/
https://ncbi.nlm.nih.gov/pubmed/15154115
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!